https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Celldex_TherapeuticsCelldex Therapeutics - Revizia istoricului2026-04-26T14:54:53ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Celldex_Therapeutics&diff=412761&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Celldex Therapeutics listata cu simbolul US.CLDX ==Descriere companie== Celldex Therapeutics, Inc. (www.celldextherapeutics.com) is a biopharmaceutical company. The Company is engaged in developing therapeutic monoclonal and bispecific antibodies. The Company's drug candidates include antibody-based therapeutics to improve the lives of patients with inflammatory diseases and many forms of cancer. The Company is engaged in the research and developmen...2024-09-18T13:47:32Z<p>Pagină nouă: Pagina dedicata companiei Celldex Therapeutics listata cu simbolul US.CLDX ==Descriere companie== Celldex Therapeutics, Inc. (www.celldextherapeutics.com) is a biopharmaceutical company. The Company is engaged in developing therapeutic monoclonal and bispecific antibodies. The Company's drug candidates include antibody-based therapeutics to improve the lives of patients with inflammatory diseases and many forms of cancer. The Company is engaged in the research and developmen...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Celldex Therapeutics listata cu simbolul US.CLDX<br />
<br />
==Descriere companie==<br />
Celldex Therapeutics, Inc. (www.celldextherapeutics.com) is a biopharmaceutical company. The Company is engaged in developing therapeutic monoclonal and bispecific antibodies. The Company's drug candidates include antibody-based therapeutics to improve the lives of patients with inflammatory diseases and many forms of cancer. The Company is engaged in the research and development of CDX-015, CDX-1140 and CDX-527. CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, has completed a Phase Ia study in healthy subjects. CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response, is being studied in a Phase I study. CDX-527 is the first candidate from Celldex's bispecific antibody platform. CDX-527 is a bispecific antibody that uses the Company's anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, and Company has initiated a Phase I study in advanced solid tumors.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.CLDX" /><br />
<br />
==Ultimele stiri despre Celldex Therapeutics (US.CLDX)==<br />
<dynamicpagelist><br />
category=US.CLDX<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.CLDX]][[Categorie:Stiri despre companii]]</div>Admin